ArticleBlood advances2026
High concordance of physician-attestation with manual data abstraction for sickle cell type: an ASH RC Data Hub study.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractSickle cell disease (SCD) is the most common inherited blood disorder in the United States. The American Society of Hematology Research Collaborative (ASH RC) has built an SCD Data Hub (DH) to facilitate research and quality improvement using real-world data. To our knowledge, we report here the first analyses from the DH, focusing on cohort demographics and accurate identification of SCD diagnosis type. DH sites have data use agreements with ASH RC to extract and transfer electronic health record (EHR) data at least quarterly. Principal investigators (PI) provided additional attestation of SCD diagnosis based on existing local data sources deemed sufficient by the PI. A random sample of 25 patients (per site) with a physician-attested diagnosis and at least 1 encounter in 2022 had SCD type and other variables manually abstracted by site personnel. Concordance was calculated as the percentage of cases with the same SCD type determined by the physician-attested and abstracted methods. Twenty DH sites have submitted data for 23 970 unique individuals with SCD. The median patient age was 23 years (range, birth to 75 years); 55.4% were female. Physician-attested SCD diagnosis types on 9484 patients from 13 sites were reported as HbSS (67.2%), HbSC (22.2%), HbSß0thalassemia (2.1%), HbSβ+thalassemia (6.1%), and HbS/other (2.4%). Physician-attested SCD type had 94% (233/248) concordance with manual chart abstraction. High concordance increases confidence in the validity of SCD DH data. Well-curated and transformed data on a large cohort of individuals with SCD will be leveraged to conduct observational studies and inform the design and feasibility of prospective interventional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.